Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

Oncotarget

Volumn 2, Issue 5, 2011, Pages 418-421

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Cancer; Chemotherapy; Proteasome inhibitor; TRAIL

Indexed keywords

BORTEZOMIB; CASPASE 8; DEATH RECEPTOR 5; PROTEASOME; PROTEIN BID; PROTEIN NOXA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; LEUKEMIA; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; SOLID TUMOR; TUMOR ESCAPE; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN FOLDING; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BORONIC ACIDS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; PYRAZINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR ESCAPE;

EID: 80053410931     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.277     Document Type: Article

References (44)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
2. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006; 25: 4798-4811.
3. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008; 19: 325-331.
4. Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009; 124: 511-515.
5. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006; 46: 189-213.
6. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget. 2011; 2: 209-221.
7. Duensing S, Duensing A. Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget. 2011; 1: 6-8.
8. Naumann I, Kappler R, von Schweinitz D, Debatin KM, Fulda S. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin Cancer Res. 2011.
9. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007; 26: 1324-1337.
10. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitinmediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem. 2000; 275: 21648-21652.
11. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005; 4: 443-449.
12. Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, Dong F, Fang B. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther. 2005; 4: 781-786.
13. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC, Jia L. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood. 2008; 111: 2797-2805.
14. Nagy K, Szekely-Szuts K, Izeradjene K, Douglas L, Tillman M, Barti-Juhasz H, Dominici M, Spano C, Luca Cervo G, Conte P, Houghton JA, Mihalik R, Kopper L, Petak I. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathol Oncol Res. 2006; 12: 133-142.
15. Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res. 2005; 11: 4259-4265.
16. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G, Gulisano M, De Maria R. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab. 2007; 92: 1938-1942.
17. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005; 65: 6282-6293.
18. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006; 107: 257-264.
19. Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H, Hale TJ, Soengas MS, Kaufman RJ, Wang CY. Proteasome inhibitor PS-341 induces apoptosis in cisplatinresistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem. 2006; 281: 31440-31447.
20. Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancerbinding protein homologous protein. Cancer Res. 2005; 65: 5662-5667.
21. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/ TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene. 2004; 23: 2554-2558.
22. Johnson TR, Stone K, Nikrad M, Yeh T, Zong W-X, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003; 22: 4953-4963.
23. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun S-Y. The proteasome inhibitor PS-341 (bortezomib) upregulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007; 67: 4981-4988.
24. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther. 2007; 6: 2103-2112.
25. Hetschko H, Voss V, Seifert V, Prehn JH, Kogel D. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis. FEBS J. 2008; 275: 1925-1936.
26. Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther. 2008; 7: 1091-1100.
27. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, Krupp W, Bauer M, Ahnert P, Meixensberger J, Walczak H. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2007; 13: 3403-3412.
28. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood. 2003; 102: 303-310.
29. Zhao X, Qiu W, Kung J, Peng X, Yegappan M, Yen-Lieberman B, Hsi ED. Bortezomib induces caspasedependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res. 2008; 32: 275-285.
30. Thorpe JA, Christian PA, Schwarze SR. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate. 2008; 68: 200-209.
31. Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E, Brocker E-B, Goebeler M, Neumann M, Walczak H. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol. 2003; 23: 777-790.
32. Inoue T, Shiraki K, Fuke H, Yamanaka Y, Miyashita K, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs. 2006; 17: 261-268.
33. Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C, Kronke M. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood. 2007; 109: 3982-3988.
34. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther. 2006; 5: 2251-2260.
35. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst. 2006; 98: 1142-1157.
36. Khan T, Stauffer JK, Williams R, Hixon JA, Salcedo R, Lincoln E, Back TC, Powell D, Lockett S, Arnold AC, Sayers TJ, Wigginton JM. Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol. 2006; 176: 6302-6312.
37. Hamner JB, Dickson PV, Sims TL, Zhou J, Spence Y, Ng CY, Davidoff AM. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery. 2007; 142: 185-191.
38. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer. 2008; 7: 50.
39. Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari Jr AW, Castle VP. Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol. 2008; 7: 135-145.
40. Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl Jr J. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol. 2006; 28: 439-446.
41. Valentiner U, Haane C, Nehmann N, Schumacher U. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model. Anticancer Res. 2009; 29: 1219-1225.
42. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008; 50: 799-805.
43. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).[erratum appears in J Clin Oncol. 2005 Jan 1;23(1): 248]. J Clin Oncol. 2004; 22: 4804-4809.
44. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007; 13: 1516-1522.